Skip to main content
Psychedex

MDA

3,4-methylenedioxyamphetamine

1Provenance card

the boundary, as counts

Sources

2910 with DOI

3 strong · 22 moderate · 4 weak

Compilations

12026-04-24T16:04:30.434Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

32last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:32:37.135Z

notice · info card · emergency

Searches

274 with no results

queries and counts on the build

Claims checked

8667 supported

67 supported · 19 not

Correspondence

0received

consent field ships in Phase 4

Edges

273

derivations recorded for this entity

Complete over 29 sources, 1 compilation, and 32 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/mda/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcPharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA
  3. 2026-10-02srcAn unusual clandestine laboratory synthesis of 3,4-methylenedioxyamphetamine (MDA)
  4. 2026-10-02srcModulation of human GABAA receptor function: a novel mode of action of drugs of abuse
  5. 2026-10-02srcThe norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans
  6. 2026-10-02srcAcute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants
  7. 2026-10-02srcEffects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats
  8. 2026-10-02srcOpioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
  9. 2026-10-02srcInvestigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans
  10. 2026-10-02srcSmall Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat
  11. 2026-10-02srcSerotonin toxicity: a practical approach to diagnosis and treatment
  12. 2026-10-02srcToxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy')
  13. 2026-10-02srcBehavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat
  14. 2026-10-02srcComparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3,4-methylenedioxyamphetamine (MDA)
  15. 2026-10-02srcThe role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity
  16. 2026-10-02srcHuman pharmacology of MDMA: pharmacokinetics, metabolism, and disposition
  17. 2026-10-02srcStereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite
  18. 2026-10-02srcPharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons
  19. 2026-10-02srcAmphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976-2004
  20. 2026-10-02srcThe impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)
  21. 2026-10-02srcEffects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors
  22. 2026-10-02srcNeurotoxicity mechanisms of thioether ecstasy metabolites
  23. 2026-10-02srcReceptor pharmacology of MDMA and related hallucinogens
  24. 2026-10-02srcDifferences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens
  25. 2026-10-02srcDrug discrimination studies with MDMA and amphetamine
  26. 2026-10-02srcRing-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex
  27. 2026-10-02srcEffects of an i.v. lethal dose of 3,4-methylenedioxyamphetamine (MDA) in the dog and antagonism by chlorpromazine
  28. 2026-10-02srcEffects of anesthesia and phenoxybenzamine on responses of dogs to IV subtoxic doses of 3,4-methylenedioxyamphetamine (MDA)
  29. 2026-10-02srcMDA Legal and Scheduling History
  30. 2026-10-02src3,4-Methylenedioxyamphetamine - Wikidoc
  31. 2026-09-04issueIssued emergency
  32. 2026-09-04issueIssued info_card
  33. 2026-09-04issueIssued notice
  34. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  35. 2026-06-04publicationPublication — backfill
  36. 2026-04-24revisionRevision 1
  37. 2026-04-24absenceSearched PubMed + OpenAlex for "Multiple final searches for tolerance, dependence, harm reduction MDA-specific" — no results
  38. 2026-04-24absenceSearched PubMed for "MDA MDMA serotonin syndrome lethal interaction opioid" — no results
  39. 2026-04-24absenceSearched PubMed for "MDA MDMA serotonin syndrome drug interaction tramadol" — no results
  40. 2026-04-24absenceSearched PubChem for "MDA 3,4-methylenedioxyamphetamine" — no results
  41. 2026-04-24genGeneration — pipeline-v5pipeline-v5
  42. 2026-04-24rungeneration run

The same entries, as forms: six forms.